Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH.

J Clin Oncol. 2019 Sep 18:JCO1901056. doi: 10.1200/JCO.19.01056. [Epub ahead of print]

PMID:
31532724
2.

Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma.

Vieyra-Garcia P, Crouch JD, O'Malley JT, Seger EW, Yang CH, Teague JE, Vromans AM, Gehad A, Win TS, Yu Z, Lowry EL, Na JI, Rook AH, Wolf P, Clark RA.

JCI Insight. 2019 Jan 10;4(1). pii: 124233. doi: 10.1172/jci.insight.124233. [Epub ahead of print]

3.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators.

Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30100375
4.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2019 Mar 1;30(3):494. doi: 10.1093/annonc/mdy207. No abstract available.

PMID:
29947731
5.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2017 Oct 1;28(10):2517-2525. doi: 10.1093/annonc/mdx352.

PMID:
28961843
6.

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.

Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH.

Mod Pathol. 2017 May;30(5):761-772. doi: 10.1038/modpathol.2016.240. Epub 2017 Jan 27.

7.

Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.

Cedeno-Laurent F, Wysocka M, Obstfeld AE, Novoa RA, Vittorio CC, Kim EJ, Weng WK, Rook AH.

J Cutan Pathol. 2017 May;44(5):462-466. doi: 10.1111/cup.12899. Epub 2017 Feb 10.

PMID:
28083948
8.

Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides.

MacArthur KM, Jariwala N, Kim EJ, Rook AH.

Acta Derm Venereol. 2017 Mar 10;97(3):373-374. doi: 10.2340/00015555-2551. No abstract available.

9.

TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients.

Jariwala N, Benoit B, Kossenkov AV, Oetjen LK, Whelan TM, Cornejo CM, Takeshita J, Kim BS, Showe LC, Wysocka M, Rook AH.

J Invest Dermatol. 2017 Jan;137(1):257-260. doi: 10.1016/j.jid.2016.08.016. Epub 2016 Sep 1. No abstract available.

10.

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Benoit BM, Jariwala N, O'Connor G, Oetjen LK, Whelan TM, Werth A, Troxel AB, Sicard H, Zhu L, Miller C, Takeshita J, McVicar DW, Kim BS, Rook AH, Wysocka M.

Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.

11.

ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.

Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER.

Cancer Cell. 2016 Jun 13;29(6):874-888. doi: 10.1016/j.ccell.2016.04.016.

12.

Polydactylous Longitudinal Melanonychia Acquired following Total Skin Electron Beam Radiation Therapy for Sézary Syndrome.

Cedeno-Laurent F, Kim EJ, Rook AH, Vittorio CC, Rubin AI.

Skin Appendage Disord. 2015 Sep;1(2):60-1. doi: 10.1159/000398817. Epub 2015 Jun 3. No abstract available.

13.

Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin.

Nattkemper LA, Martinez-Escala ME, Gelman AB, Singer EM, Rook AH, Guitart J, Yosipovitch G.

Acta Derm Venereol. 2016 Nov 2;96(7):894-898. doi: 10.2340/00015555-2417.

14.

The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.

Spaccarelli N, Rook AH.

Dermatol Clin. 2015 Oct;33(4):731-45. doi: 10.1016/j.det.2015.05.008. Epub 2015 Aug 20. Review.

15.

Global Quantitative Techniques for Positron Emission Tomographic Assessment of Disease Activity in Cutaneous T-Cell Lymphoma and Response to Treatment.

Fardin S, Gholami S, Samimi S, Rook AH, Alavi A.

JAMA Dermatol. 2016 Jan;152(1):103-5. doi: 10.1001/jamadermatol.2015.2706. No abstract available.

PMID:
26422531
16.

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA.

Blood. 2015 Sep 17;126(12):1452-61. doi: 10.1182/blood-2015-02-630335. Epub 2015 Jul 30. Erratum in: Blood. 2015 Dec 17;126(25):2765. Gelfand, Joel C [corrected to Gelfand, Joel M].

17.

Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S.

Leuk Lymphoma. 2015;56(10):2847-54. doi: 10.3109/10428194.2015.1014360. Epub 2015 May 20.

18.

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.

Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.

Clin Immunol. 2015 May;158(1):1-7. doi: 10.1016/j.clim.2015.02.014. Epub 2015 Mar 8.

19.

Merkel cell polyomavirus in low levels in folliculotropic mycosis fungoides represents a passenger, not a driver.

Gormley RH, Kim EJ, Rook AH, Kovarik CL, Sun A, Rady P, Tyring SK.

Int J Dermatol. 2015;54(5):e182-3. doi: 10.1111/ijd.12754. Epub 2015 Feb 6. No abstract available.

PMID:
25661198
20.

Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas.

Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A.

Hell J Nucl Med. 2014 May-Aug;17(2):78-84. doi: 10.1967/s002449910131. Epub 2014 Jul 5. Review.

21.

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL.

Cancer. 2014 Aug 15;120(16):2464-71. doi: 10.1002/cncr.28712. Epub 2014 Apr 25.

22.

Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.

Huen AO, Rook AH.

Curr Opin Oncol. 2014 Mar;26(2):237-44. doi: 10.1097/CCO.0000000000000048. Review.

PMID:
24441505
23.

CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.

J Invest Dermatol. 2014 Jan;134(1):229-236. doi: 10.1038/jid.2013.279. Epub 2013 Jun 21.

24.

TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA.

Clin Cancer Res. 2013 Jul 15;19(14):3755-63. doi: 10.1158/1078-0432.CCR-12-3488. Epub 2013 Jun 19.

25.

IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.

Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, Loren AW, Dentchev T, Wysocka M, Yosipovitch G, Rook AH.

J Invest Dermatol. 2013 Dec;133(12):2783-2785. doi: 10.1038/jid.2013.227. Epub 2013 May 22. No abstract available.

26.

Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.

Klein RS, Dunlop JD, Samimi SS, Morrissey KA, Evans KG, Gardner JM, Introcaso CE, Vittorio CC, Rook AH, Micaily B, Kim EJ.

J Am Acad Dermatol. 2013 Jun;68(6):972-7. doi: 10.1016/j.jaad.2012.09.056. Epub 2013 Feb 12.

PMID:
23415461
27.

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH.

JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541.

28.

Progress in immunotherapy of cancer.

Rook AH, Raphael BA.

N Engl J Med. 2012 Sep 20;367(12):1168; author reply 1168. doi: 10.1056/NEJMc1208946. No abstract available.

PMID:
22992095
29.

Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.

Kim YH, Demierre MF, Kim EJ, Lerner A, Rook AH, Duvic M, Robak T, Samtsov A, McCulloch W, Chen SC, Waksman J, Nichols J, Whittaker S.

Leuk Lymphoma. 2013 Feb;54(2):284-9. doi: 10.3109/10428194.2012.711829. Epub 2012 Aug 17.

PMID:
22839723
30.

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong R, Weng WK, Showe LC, Wysocka M, Rook AH.

Am J Hematol. 2012 Apr;87(4):354-60. doi: 10.1002/ajh.23112. Epub 2012 Feb 24.

31.

The beauty of TLR agonists for CTCL.

Rook AH.

Blood. 2012 Jan 12;119(2):321-2. doi: 10.1182/blood-2011-11-391243. No abstract available. Erratum in: Blood. 2013 Oct 10;122(15):2765.

32.

Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.

Stephen S, Morrissey KA, Benoit BM, Kim EJ, Vittorio CC, Nasta SD, Showe LC, Wysocka M, Rook AH.

Am J Hematol. 2012 Feb;87(2):226-8. doi: 10.1002/ajh.22231. Epub 2011 Dec 21.

33.

Chronic acyclovir-resistant HSV-2 ulcer in an immunosuppressed patient treated with topical cidofovir.

Evans KG, Morrissey KA, Goldstein SC, Vittorio CC, Rook AH, Kim EJ.

Arch Dermatol. 2011 Dec;147(12):1462-3. doi: 10.1001/archderm.147.12.1462. No abstract available.

PMID:
22184781
34.

The relevance of photopheresis to autoreactive diseases.

Samimi S, Rook AH.

Clin Immunol. 2012 Feb;142(2):97-100. doi: 10.1016/j.clim.2011.11.003. Epub 2011 Nov 11. No abstract available.

PMID:
22134055
35.

Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas.

Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL.

Bone Marrow Transplant. 2012 Jul;47(7):940-5. doi: 10.1038/bmt.2011.201. Epub 2011 Oct 24.

36.

Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.

Nagler AR, Samimi S, Schaffer A, Vittorio CC, Kim EJ, Rook AH.

J Am Acad Dermatol. 2012 Mar;66(3):503-8. doi: 10.1016/j.jaad.2011.06.014. Epub 2011 Oct 17. Review.

PMID:
22005074
37.

Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.

Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA.

PLoS One. 2011;6(9):e24849. doi: 10.1371/journal.pone.0024849. Epub 2011 Sep 16.

38.

Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Wysocka M, Dawany N, Benoit B, Kossenkov AV, Troxel AB, Gelfand JM, Sell MK, Showe LC, Rook AH.

Leuk Lymphoma. 2011 Oct;52(10):1970-9. doi: 10.3109/10428194.2011.582202.

39.

Congestive heart failure in a patient with cutaneous T-cell lymphoma treated with low-dose interferon alfa-2b.

Evans KG, Loren AW, Rook AH, Kim EJ, Glassberg HL.

Arch Dermatol. 2011 Sep;147(9):1122-3. doi: 10.1001/archdermatol.2011.246. No abstract available.

PMID:
21931064
40.

High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.

Raphael BA, Shin DB, Suchin KR, Morrissey KA, Vittorio CC, Kim EJ, Gardner JM, Evans KG, Introcaso CE, Samimi SS, Gelfand JM, Rook AH.

Arch Dermatol. 2011 Dec;147(12):1410-5. doi: 10.1001/archdermatol.2011.232. Epub 2011 Aug 15.

PMID:
21844430
41.

Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma.

Raphael BA, Morrissey KA, Kim EJ, Vittorio CC, Rook AH.

J Am Acad Dermatol. 2011 Jul;65(1):212-4. doi: 10.1016/j.jaad.2010.06.056. No abstract available.

PMID:
21679821
42.

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.

Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST.

Leuk Lymphoma. 2011 Aug;52(8):1474-80. doi: 10.3109/10428194.2011.572265. Epub 2011 Jun 8.

PMID:
21649541
43.

Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome.

Evans KG, Troxel AB, DeNardo BJ, Introcaso CE, Rook AH, Kim EJ.

J Am Acad Dermatol. 2011 Apr;64(4):682-9. doi: 10.1016/j.jaad.2009.01.044. Epub 2011 Feb 18.

PMID:
21315479
44.

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M.

J Am Acad Dermatol. 2011 Feb;64(2):352-404. doi: 10.1016/j.jaad.2010.08.037. Epub 2010 Dec 9. Review.

PMID:
21145619
45.

A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.

Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B.

J Am Acad Dermatol. 2010 Dec;63(6):984-90. doi: 10.1016/j.jaad.2010.02.039.

PMID:
20889234
46.

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH.

J Am Acad Dermatol. 2010 Dec;63(6):975-83. doi: 10.1016/j.jaad.2009.12.052.

PMID:
20888065
47.

Immune modulators as therapeutic agents for cutaneous T-cell lymphoma.

Rook AH, Benoit B, Kim EJ, Vittorio CC, Anshelevich A, Raphael BA, Introcaso CE, Gardner JM, Evans KG, Morrissey K, Samimi S, Musiek AC, Showe LC, Wasik MA, Wysocka M.

Clin Lymphoma Myeloma Leuk. 2010 Sep;10 Suppl 2:S93-5. doi: 10.3816/CLML.2010.s.017. No abstract available.

48.

Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.

Samimi S, Benoit B, Evans K, Wherry EJ, Showe L, Wysocka M, Rook AH.

Arch Dermatol. 2010 Dec;146(12):1382-8. doi: 10.1001/archdermatol.2010.200. Epub 2010 Aug 16.

49.

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH.

J Clin Oncol. 2010 Oct 10;28(29):4485-91. doi: 10.1200/JCO.2010.28.9066. Epub 2010 Aug 9.

PMID:
20697094
50.

Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.

Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ.

J Am Acad Dermatol. 2010 Feb;62(2):300-7. doi: 10.1016/j.jaad.2009.02.035. Epub 2009 Nov 26. Review.

PMID:
19944484

Supplemental Content

Support Center